ClinicalTrials.gg

Program

ramantamig

Also written as “JNJ-79635322” and “Ramantamig”.

Its studies are mostly in Multiple Myeloma, led by Johnson & Johnson.

Furthest: phase 3, since Nov 21, 20257 company-led studies, 7 open or runningNext primary completion: Apr 19, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson77 open or runningphase 3since Nov 21, 2025Dec 7, 2022Apr 19, 2027phase 1 · NCT05652335
  • Named in Johnson & Johnson’s own pipeline as ramantamig, phase 3, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 7, 2022First study: phase 1 study in RecurrenceFirst studyNCT05652335 · 180 planned · United States, Belgium, France and more
  2. Jul 8, 2024Phase 2 study in Multiple MyelomaNCT06500884 · 210 planned · United States, Brazil, Netherlands and more
  3. Nov 21, 2025Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07258511 · 400 planned · United States, Australia, Brazil and more
  4. Nov 25, 2025Phase 2 study in Multiple MyelomaNCT07266441 · 168 enrolled · United States, China, Israel and more
  5. Apr 1, 2026Phase 3 study in Multiple MyelomaNCT07518186 · 700 planned · United States, Australia, Brazil and more
  6. Jun 18, 2026Phase 3 study in Multiple MyelomaNCT07665450 · 1,000 planned · Australia, Czechia, France and more
  7. Oct 23, 2026Phase 3 study in Multiple MyelomaNCT07903272 · 1,000 planned

Ahead

  1. Apr 19, 2027Primary completion: phase 1 study in RecurrenceNCT05652335
  2. Jun 14, 2027Primary completion: phase 2 study in Multiple MyelomaNCT07266441
  3. Dec 12, 2028Primary completion: phase 3 study in Multiple MyelomaNCT07258511
  4. Apr 29, 2029Primary completion: phase 3 study in Multiple MyelomaNCT07518186

TargetBeta

“A T-cell engager and trispecific antibody targeting the two tumor-associated antigens (TAAs) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and human G-protein coupled receptor family C group 5 member D (GPRC5D), and the T-cell surface antig…”NCIt, read by Claude
“A T-cell engager and trispecific antibody targeting the two tumor-associated antigens (TAAs) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and human G-protein coupled receptor family C group 5 member D (GPRC5D), and the T-cell surface antigen ”NCIt, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07903272Multiple Myeloma3Not yet recruitingJan 11, 20371,000
NCT07665450Multiple Myeloma · Australia, Czechia, France and more3RecruitingSep 4, 20301,000
NCT07518186Multiple Myeloma · United States, Australia, Brazil and more3RecruitingApr 29, 2029700
NCT07266441Multiple Myeloma · United States, China, Israel and more2Active, not recruitingJun 14, 2027168
NCT07258511Multiple Myeloma · United States, Australia, Brazil and more3RecruitingDec 12, 2028400
NCT06500884Multiple Myeloma · United States, Brazil, Netherlands and more2RecruitingMay 30, 2030210
NCT05652335Recurrence · United States, Belgium, France and more1RecruitingApr 19, 2027180

How it is read

Names in the registry

  • “JNJ-79635322”, 4 entries
  • “Ramantamig”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.